

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-000288

**Date:** 26/9/23

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see response below

Request

I am trying to understand how Pembrolizumab is used in the treatment of Melanoma. Could you please answer the following:

Q1. How many patients have you treated with Pembrolizumab in the three months from May 2023 to July 2023 for:

- Melanoma - any stage
- Stage IIb/IIc Melanoma
- Stage III Melanoma
- Metastatic Melanoma

Q2. How many Stage IIb/IIc melanoma patients were on a "Watch and Wait" strategy in the three months from May 2023 to July 2023? These would be patients where a decision has been made to wait before commencing any treatment. -

Response

Melanoma patients would be treated at New Cross Hospital, Wolverhampton.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**